Victorian Evolution of Inherited Retinal Diseases Natural History Registry (VENTURE study): Rationale, methodology, and initial participant characteristics

Britten-Jones, Alexis C., O'Hare, Fleur, Edwards, Thomas L., Ayton, Lauren N., Jolly, Jasleen K. and VENTURE Study Consortium (2022) Victorian Evolution of Inherited Retinal Diseases Natural History Registry (VENTURE study): Rationale, methodology, and initial participant characteristics. Clinical and Experimental Ophthalmology. ISSN 1442-9071

[img] Text
Accepted Version
Restricted to Repository staff only until 27 May 2023.
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Request a copy
Official URL: https://doi.org/10.1111/ceo.14110

Abstract

Background- Emerging treatments are being developed for inherited retinal diseases, requiring a clear understanding of natural progression and a database of potential participants for clinical trials. This article describes the rationale, study design, and methodology of the Victorian Evolution of inherited retinal diseases NaTUral History REgistry (VENTURE), including data from the first 150 participants enrolled. Methods- VENTURE collects retrospective and prospective data from people with inherited retinal diseases. Following registration, participants are asked to attend a baseline examination using a standardised protocol to confirm their inherited retinal disease diagnosis. Examination procedures include i) retinal function, using visual acuity and perimetry; ii) retinal structure, using multimodal imaging; and iii) patient-reported outcomes. Participants’ molecular diagnoses are obtained from their clinical records or through targeted-panel genetic testing by an independent laboratory. Phenotype and genotype data are used to enrol participants into disease-specific longitudinal cohort sub-studies. Results- From 7 July 2020 and 30 December 2021, VENTURE enrolled 150 registrants (138 families) and most (63%) have a rod-cone dystrophy phenotype. From 93 participants who have received a probable molecular diagnosis, the most common affected genes are RPGR (13% of all registrants), USH2A (10%), CYP4V2 (7%), ABCA4 (5%), and CHM (5%). Most participants have early to moderate vision impairment, with over half (55%) having visual acuities of better than 6/60 (20/200) at registration. Conclusions- The VENTURE study will complement existing patient registries and help drive inherited disease research in Australia, facilitating access to research opportunities for individuals with inherited retinal diseases.

Item Type: Journal Article
Keywords: Inherited, Gene therapy, Rod-cone dystrophies (retinitis pigmentosa), Genetic disease, Retinal disease
Faculty: Faculty of Health, Education, Medicine & Social Care
Depositing User: Ian Walker
Date Deposited: 25 May 2022 09:47
Last Modified: 31 May 2022 16:17
URI: https://arro.anglia.ac.uk/id/eprint/707636

Actions (login required)

Edit Item Edit Item